Conference Coverage

Complete Conference Coverage

Explaining Androgen Receptor-indifferent Prostate Cancer

Explaining Androgen Receptor-indifferent Prostate Cancer

Physicians will speak about tumor evolution and AR-indifferent disease at the 2017 ASCO Genitourinary Cancers Symposium in Orlando, Florida.

Safety of Active Surveillance for Small Renal Masses

Safety of Active Surveillance for Small Renal Masses

Active surveillance appears to be a safe alternative to primary intervention for selected patients with small renal masses.

Dual Immunotherapy Active vs Sunitinib for PD-L1+ Advanced RCC

Dual Immunotherapy Active vs Sunitinib for PD-L1+ Advanced RCC

Atezolizumab (Tecentriq) combined with bevacizumab (Avastin) demonstrated antitumor activity compared with sunitinib as first-line therapy.

Genomic Alterations in Metastatic Renal Cell Carcinoma

Genomic Alterations in Metastatic Renal Cell Carcinoma

Patients with metastatic renal carcinoma (mRCC) treated with post-frontline agents had increased genomic alterations.

Adjuvant BEP for 1 Cycle Safe, Efficacious for Testicular Cancer

Adjuvant BEP for 1 Cycle Safe, Efficacious for Testicular Cancer

Bleomycin, etoposide, and cisplatin (BEP) for 1 cycle after orchiectomy is associated with a similar 2-year recurrence rate as BEP.

Urothelial Carcinoma: Year in Review

Urothelial Carcinoma: Year in Review

Studies presented in the last year demonstrated a revolutionary role for immune checkpoint inhibitors.

Pembrolizumab Improves Survival and Quality of Life in Advanced Bladder Cancer

Pembrolizumab Improves Survival and Quality of Life in Advanced Bladder Cancer

Pembrolizumab following platinum-based chemotherapy was associated with significantly longer overall survival, fewer adverse events.

Bladder Cancer: Genomics May Predict Benefit from Neoadjuvant Chemotherapy

Bladder Cancer: Genomics May Predict Benefit from Neoadjuvant Chemotherapy

David J. McConkey, MD, PhD, described how genomics can affect the clinical management of patients with bladder cancer.

Bladder Cancer: Neoadjuvant Chemotherapy and Molecular Subtype

Bladder Cancer: Neoadjuvant Chemotherapy and Molecular Subtype

The clinical outcomes when using neoadjuvant chemotherapy for muscle-invasive bladder cancer vary by molecular subtype.

Chemo + Radiotherapy Efficacious in Muscle-invasive Bladder Cancer

Chemo + Radiotherapy Efficacious in Muscle-invasive Bladder Cancer

Adding chemotherapy with fluorouracil and mitomycin to radiotherapy improves locoregional control.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs